ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: QLT Inc. (QLTI) Report Updated: Jul 25, 2016 | Print This Page

Get more stock ratings by Louis Navellier

QLT Inc. (QLTI)

Rating: Strong Sell Volatility: Conservative
Total Grade: F Industry: Biotechnology
Competitors: AVXL,FPRX,DMPI,SPHS

Stock Analysis

Rating: Monthly View

A
B
C
D
F
July August September October November December January February March April May June

Rating: Weekly View

This Week: F down no change
Last Week: F same no change
Two Weeks Ago: F up no change
service keys

QLT Inc.© quotemedia

Company Profile

QLT Inc., a biotechnology company, engages in the development and commercialization of ocular products that address the unmet medical needs of patients and clinicians worldwide. The company focuses on the development of QLT091001, a synthetic retinoid compound, which has been completed Phase Ib retreatment clinical trials for the treatment of leber congenital amaurosis and retinitis pigmentosa; Phase Ib clinical trials for the treatment of Retinitis Pigmentosa with autosomal dominant mutation in RPE65; and Phase IIa clinical trials for the treatment of impaired dark adaptation. QLT Inc. was founded in 1981 and is headquartered in Vancouver, Canada.